Acadia pharmaceuticals announces top-line results from phase 2 study evaluating acp-044 for the treatment of acute postoperative pain

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced top-line results from a phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of acp-044 for acute pain following bunionectomy surgery. the primary endpoint, a comparison of cumulative pain intensity scores over 24 hours between the acp-044 1600 mg once daily, acp-044 400 mg four times daily and placebo treatment arms, was not met. a trend favoring the acp-044
ACAD Ratings Summary
ACAD Quant Ranking